Abstract:Vascular senescence has been implicated in atherosclerotic arterial disease clinically and in animals. Senescence induction conditions include telomere and mitochondrial dysfunction, DNA damage, and elevated oxidative stress. Alpha-lipoic acid (ALA) is a powerful natural antioxidant, implying a potential important role of ALA in senescence pathogenesis. We showed recently peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) is a primary negative regulator of vascular senescence. We thus posited that ALA may inhibit vascular senescence via enabling PGC-1 alpha signaling networks. We generated a PGC-1 alpha and ApoE double knockout mouse model and show that mice with PGC-1 alpha deficiency develop a senescence phenotype (2.25 fold) that is associated with increased cellular general ROS levels (3 fold) and mitochondrial superoxide production (2 fold). We demonstrate that ALA (100 μM for in vitro, 10 mg/kg/d for in vivo experiments) upregulates expression of PGC-1 alpha and PGC-1 alpha-dependent downstream ROS defense molecules, including SIRT1, catalase, MnSOD, heme oxygenase 1 (HO-1), and its mitochondrial targets including NRF-1 and 2, and TFAM, while decreases expression of the senescence marker p53 in mice aortas and vascular smooth muscle cells (VSMC). The upregulation of the endogenous antioxidants and mitochondrial targets is prevented by PGC-1 alpha deficiency. Further, ALA (100 μM) is sufficient to inhibit and reverse VSMC senescence through a blockade of PGC-1 alpha acetylation, thus preventing the downregulation of SIRT1 and catalase triggered by angiotensin II (Ang II), a major hormonal inducer of vascular senescence. Moreover, ALA inhibits Ang II-induced cellular ROS and mitochondrial superoxide production, both of which are abolished in the absence of PGC-1 alpha. Our findings show that ALA is an important activator of PGC-1 alpha signaling pathways and unravel a previously unappreciated role for ALA in mitigating oxidative stress-dependent vascular senescence via PGC-1 alpha. These observations support the notion that enabling of PGC-1 alpha signaling network might be a promising strategy in the development of intervention for oxidative stress-dependent, age-related, chronic diseases.

Alpha-lipoic Acid Attenuates Cardiac Hypertrophy Via Downregulation of PARP-2 and Subsequent Activation of SIRT-1.

Aliskiren Ameliorates Pressure Overload-Induced Heart Hypertrophy and Fibrosis in Mice

Lipoamide Attenuates Hypertensive Myocardial Hypertrophy Through PI3K/Akt-Mediated Nrf2 Signaling Pathway

PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.

Allicin Protects Against Cardiac Hypertrophy and Fibrosis Via Attenuating Reactive Oxygen Species-Dependent Signaling Pathways.

Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy

α-Lipoic acid Prevents Angiotensin II-induced Endothelial Dysfunction via Antioxidant Effect and PI3K/Akt/eNOS Signaling Pathway

Alpha-lipoic Acid Protects Against Aortic Aneurysm and Dissection by Improving Vascular Smooth Muscle Cell Function.

AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.

Asiatic Acid Protects Against Cardiac Hypertrophy Through Activating Ampka Signalling Pathway

Cardioprotective Effect of Alpha-Lipoic Acid and Its Mechanisms

5-Aminolevulinic Acid Combined with Sodium Ferrous Citrate Ameliorates H2O2-induced Cardiomyocyte Hypertrophy Via Activation of the MAPK/Nrf2/HO-1 Pathway

Salvianolic acid B protects cardiomyocytes from angiotensin II-induced hypertrophy via inhibition of PARP-1

Abstract 19679: Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) Ameliorates Angiotensin II-Induced Cardiac Remodeling and Myocardial Dysfunction through Inhibition of Mitochondrial Oxidative Stress and Induction of Autophagy

The novel peptide athycaltide-1 attenuates Ang II-induced pathological myocardial hypertrophy by reducing ROS and inhibiting the activation of CaMKII and ERK1/2

Alpha lipoic acid protects heart against myocardial ischemia-reperfusion injury through a mechanism involving aldehyde dehydrogenase 2 activation.

Synthesis of the Novel PARP-1 Inhibitor AG-690/11026014 and Its Protective Effects on Angiotensin II-induced Mouse Cardiac Remodeling

Activation of aldehyde dehydrogenase 2 slows down the progression of atherosclerosis via attenuation of ER stress and apoptosis in smooth muscle cells

Alpha-lipoic acid impedes myocardial ischemia-reperfusion injury, myocardial apoptosis, and oxidative stress by regulating HMGB1 expression

Role of PARP-2 in cardiac hypertrophy in rats

Abstract 9958: Enabling of PGC-1 Alpha Signaling by Alpha-lipoic Acid Inhibits and Reverses Vascular Senescence